iRhythm Technologies, Inc. Profile Avatar - Palmy Investing

iRhythm Technologies, Inc.

iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that com…

Medical - Devices
US, San Francisco [HQ]

FA

Fundamental Analysis · Most Recent Quarter

It is important to understand the FA Algorithm and the criterias before valuing it as a top-tier resource.

Read Rationale
Framework:
Valuation 28% Weak
Profitability n.A. n.A.
Fin. Growth 33% Weak
Leverage & Liquidity 17% Weak
Per Share Metrics 33% Weak
Fin. Health n.A. n.A.
Fundamentals

Valuation

Metric Q4 Q1 Δ in %
EV/EBITDA 23.37 -119.71 -156.21
Graham Fair Price -29.55 9.81 13.93
PEG -130.64 -1.18 -0.51
Price/Book 153.90 39.71 15.64
Price/Cash Flow 47.94 -58.02 -111.44
Prices/Earnings 7.53 -19.63 -21.23
Price/Sales 9.60 27.18 24.80
Price/FCF 47.94 -58.02 -111.44
Naive Interpretation member
01 - Valuation · Weak
Fundamentals

Profitability

Metric Q4 Q1 Δ in %
Gross Profit Margin 0.54 0.66 0.66
Operating Margin -36.30 -0.29 -0.21
ROA 43.82 -0.05 -0.09
ROE -0.18 -0.51 -174.59
ROIC -0.11 -0.05 53.17
Naive Interpretation member
02 - Profitability · Not Interpreted
Fundamentals

Financial Growth

Metric Q4 Q1 Δ in %
Debt QOQ 4.68 -0.01 32140.64
Dividends QOQ 0.00 0.00 0.00
EBIT QOQ -0.02 -0.36 -1867.09
EPS QOQ -0.42 -0.17 59.91
FCF QOQ -2.74 -1.10 59.96
Revenue QOQ 0.06 < 0.005 -93.08
Naive Interpretation member
03 - Financial Growth · Weak
Fundamentals

Leverage & Liquidity

Metric Q4 Q1 Δ in %
Assets Turnover n.A. n.A. n.A.
Days Inventory Outstanding (DIO) 27.89 30.14 8.05
Days Sales Outstanding (DSO) 41.76 61.20 46.55
Inventory Turnover 3.23 2.99 -7.45
Debt/Capitalization 0.19 0.88 356.74
Quick Ratio 1.82 6.80 274.10
Naive Interpretation member
04 - Leverage & Liquidity · Weak
Fundamentals

Per Share Metrics

Metric Q4 Q1 Δ in %
Book Value 6.84 2.91 -57.48
Cash 4.36 18.34 320.91
Capex -0.44 -0.32 28.45
Free Cash Flow -0.96 -1.99 -107.35
Revenue 4.32 4.25 -1.50
Naive Interpretation member
05 - Per Share Metrics · Weak
Fundamentals

Financial Health

Metric Q4 Q1 Δ in %
Current Ratio 2.15 7.10 230.22
Debt/Assets n.A. n.A. n.A.
Debt/Equity n.A. n.A. n.A.
Net Debt/EBITDA -4.33 -6.82 -57.54
Naive Interpretation Member
06 - Financial Health · Bad
End of IRTC's Analysis
CIK: 1388658 CUSIP: 450056106 ISIN: US4500561067 LEI: - UEI: -
Secondary Listings
IRTC has no secondary listings inside our databases.